Document is current
Any future updates will be listed below
-
Authors
Malone, Samantha G. https://orcid.org/0000-0002-8498-4208
Davis, Christal N. https://orcid.org/0000-0003-3974-5598
Piserchia, Zachary
Setzer, Michael R.
Toikumo, Sylvanus https://orcid.org/0000-0002-6024-0693
Zhou, Hang https://orcid.org/0000-0002-7694-6391
Winterlind, Emma L.
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Justice, Amy https://orcid.org/0000-0003-0139-5502
Leggio, Lorenzo
Rentsch, Christopher T. https://orcid.org/0000-0002-1408-7907
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Gray, Joshua C. https://orcid.org/0000-0002-5351-561X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01 AA030056, R01AA030041)
U.S. Department of Defense (HU0001-22-2-0066)
- License Information
-
More Information
Article History
Received: 3 May 2024
Accepted: 20 February 2025
First Online: 31 March 2025
Competing interests
: H.R.K. is a member of advisory boards for Altimmune, Clearmind Medicine, Dicerna Pharmaceuticals, Enthion Pharmaceuticals, Lilly Pharmaceuticals and Sophrosyne Pharmaceuticals; a consultant to Sobrera Pharmaceuticals and Altimmune; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the past 3 years by Alkermes, Dicerna, Ethypharm, Imbrium, Indivior, Kinnov, Lilly, Otsuka and Pear. J.G. and H.R.K. hold US patent 10,900,082 titled ‘Genotype-guided dosing of opioid agonists’, issued 26 January 2021. J.G. is paid for editorial work for the journal Complex Psychiatry. The other authors declare no competing interests.
